267 related articles for article (PubMed ID: 34455072)
1. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
2. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
3. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
[TBL] [Abstract][Full Text] [Related]
4. Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.
Ali F; Alom S; Shakya A; Ghosh SK; Singh UP; Bhat HR
Arch Pharm (Weinheim); 2022 May; 355(5):e2100360. PubMed ID: 35244237
[TBL] [Abstract][Full Text] [Related]
5. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
7. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ
Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
9. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Deshpande RR; Tiwari AP; Nyayanit N; Modak M
Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of anisomycin and oleandomycin as a potential anti-(SARS-CoV-2) virus targeting key enzymes using virtual computational approaches.
Zrieq R; Snoussi M; Algahtan FD; Tasleem M; Saeed M; Noumi E; Khalifa NE; Gad-Elkareem MAM; Aouadi K; Kadri A
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):387-398. PubMed ID: 35818229
[TBL] [Abstract][Full Text] [Related]
11. A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism.
Yao Y; Zhang Y; Li Z; Chen Z; Wang X; Li Z; Yu L; Cheng X; Li W; Jiang WJ; Wu HJ; Feng Z; Sun J; Fei T
Biochem Biophys Res Commun; 2023 Oct; 675():113-121. PubMed ID: 37467664
[TBL] [Abstract][Full Text] [Related]
12. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.
Cavasotto CN; Di Filippo JI
Mol Inform; 2021 Jan; 40(1):e2000115. PubMed ID: 32722864
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new drug indications for COVID-19: A drug repurposing approach.
Kumari P; Pradhan B; Koromina M; Patrinos GP; Steen KV
PLoS One; 2022; 17(5):e0267095. PubMed ID: 35609015
[TBL] [Abstract][Full Text] [Related]
15. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
[TBL] [Abstract][Full Text] [Related]
17.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
18. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
19. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
20. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]